(Q40331917)

19 September 2017

1 reference

title

The clinical pharmacology of VM26 and VP16-213. A brief overview (English)

1 reference

19 September 2017

1 reference

P J Creaven

1

1 reference

19 September 2017

publication date

1 January 1982

1 reference

Cancer Chemotherapy and Pharmacology

19 September 2017

published in

1 reference

19 September 2017

volume

7

1 reference

19 September 2017

issue

2-3

1 reference

19 September 2017

page(s)

133-140

1 reference

PTG, a new antineoplastic epipodophyllotoxin

19 September 2017

cites work

1 reference

12 December 2020

Podophyllotoxin derivative VP 16-213

1 reference

12 December 2020

Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213)

1 reference

12 December 2020

PHASE I clinical trial of an oral solution of VP-16-213

1 reference

12 December 2020

Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivatives

1 reference

12 December 2020

VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules

1 reference

12 December 2020

Analysis of the anticancer drugs VP 16-213 and VM 26 and their metabolites by high-performance liquid chromatography

1 reference

12 December 2020

Etoposide (VP-16-213)

1 reference

12 December 2020

The role of drug disposition kinetics on cellular transport of the antineoplastic agent VM-26

1 reference

12 December 2020

VM 26 and VP 16-213: a comparative analysis

1 reference

12 December 2020

EPEG, a new antineoplastic epipodophyllotoxin

1 reference

12 December 2020

A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213

1 reference

12 December 2020

High-performance liquid chromatography determination of 4'-demethyl-epipodophyllotoxin-9-(4,6-O-ethylidene beta-D-glucopyranoside) (VP 16-213) in human plasma

1 reference

12 December 2020

Phase I trial of a new form of an oral administration of VP-16-213

1 reference

12 December 2020

Comparison of uptake and binding of two epipodophyllotoxin glucopyranosides, 4'-demethyl epipodophyllotoxin thenylidene-beta-D-glucoside and 4'-demethyl epipodophyllotoxin ethylidene-beta-D-glucoside, in the L1210 leukemia cell

1 reference

12 December 2020

Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies

1 reference

12 December 2020

Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease

1 reference

12 December 2020

Phase II study of VM-26 in adult malignancies

1 reference

12 December 2020

Analysis of 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) by high-pressure liquid chromatography

1 reference

12 December 2020

Comparison of the biologic activity of VP-16-213 given iv and orally in capsules or drink ampules

1 reference

12 December 2020

Phase II study of VM-26 in acute leukemia, neuroblastoma, and other refractory childhood malignancies: a report from the Children's Cancer Study Group

1 reference

12 December 2020

Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213)

1 reference

12 December 2020

4′-Demethyl-epipodophyllotoxin-β-d-thenylidene glucoside (VM-26)—A brief review

1 reference

12 December 2020

Multicompartment pharmacokinetic model of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) in humans

1 reference

12 December 2020

Clinical studies with a new podophyllotoxin derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidine- -D-glucopyranoside) (NSC-122819).

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF00254535

1 reference

Dimensions Publication ID

19 September 2017

1025069759

0 references

1 reference